S-0139 Shionogi

Current Opinion in Investigational Drugs

Volumn 3, Issue 7, 2002, Pages 1051-1056

  Wu Wong, J Ruth ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; ANTIHYPERTENSIVE AGENT; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST;

BRAIN ISCHEMIA; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; EXPERIMENTAL MODEL; HUMAN; HYPERTENSION; NONHUMAN; PHASE 2 CLINICAL TRIAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CAFFEIC ACIDS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DRUG INDUSTRY; HUMANS; OLEANOLIC ACID; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN;

EID: 0036667169     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. 165965 Update on endothelin research. Battistini B, Warner TD, Corder R Drug News Perspect 1994 7 249-253
2. 223386 Drug development pipeline. Shionogi & Co Ltd Company Communication 1996 October 18
3. 226884 Characterization of endothelin receptors in the human pulmonary vasculature using bosentan, SB209670, and 97-139. Russell FD, Davenport AP J Cardiovasc Pharmacol 1995 26 Suppl 3 S346-S347
4. 235771 Endothelin receptors: Receptor classification, novel receptor antagonists, and potential therapeutic targets. Ohlstein EH, Elliott JD, Feuerstein GZ, Ruffolo RR Jr Med Res Rev 1996 4 363-390
5. 247179 Amelioration of glycerol-induced acute renal failure in rats by an endothelin A receptor antagonist (S-0139). Shimizu T, Kuroda T, Hata K, Fujimoto M Jpn J Pharmacol 1997 73 Suppl 1 O-236
6. 248001 Effects of an endothelin A receptor antagonist, S-0139, on intrathecally endothelin-treated dogs. Sato S, Yonetani Y, Kita T, Kubo K, Nakashima T Jpn J Pharmacol 1997 73 1 P-370
7. 252007 70th Annual Meeting of the Japanese Pharmacological Society. Pharma Jpn 1997 1544 15-16
8. 257833 Endothelins: Roles in pulmonary diseases, ATS/ALA Annual Meeting, San Francisco, CA, USA. IDDB Meeting Report 1997 May 17-21
9. 263175 Binding characterization of S-0139, an endothelin ETA receptor antagonist. Mihara SI, Tozawa F, Fujimoto M Jpn J Pharmacol 1997 73 Suppl 1 P-143
10. 263176 Protective effects of an active endothelin receptor antagonist, S-0139, in rats with monocrotaline-induced pulmonary hypertension. Nakajima S, Kawabata T, Kawakami M, Shimamura T, Iwaki K Jpn J Pharmacol 1997 73 Suppl 1 P-56
11. 263177 Protective effect of an endothelin ETA receptor antagonist, S-0139, on brain injury after transient middle cerebral artery occlusion in rats. Matsuo Y, Mihara S, Gemba T, Notoya M, Ninomiya M, Fujimoto M Jpn J Pharmacol 1997 73 Suppl 1 O-196
12. 263178 ICAM-1 expression induced by endothelins on rat cardiac myocytes and aortic endothelial cells. Hayasaki Y, Nakajima M, Kitano Y, Iwasaki T, Shimamura T, Iwaki K Jpn J Pharmacol 1997 73 Suppl 1 O-18
13. 263179 ICAM-1 expression on cardiac myocytes and aortic endothelial cells via their specific endothelin receptor subtype. Hayasaki Y, Nakajima M, Kitano Y, Iwasaki T, Shimamura T, Iwaki K Biochem Biophys Res Commun 1996 229 3 817-824
14. 263182 Effect of an endothelin A receptor antagonist, S-0139, on delayed cerebral vasospasm in the canine two-hemorrhage model. Kita T, Kubo K, Narushima I, Sato S, Matsuura E, Yonetani Y, Nakashima T Jpn J Pharmacol 1997 73 Suppl 1 90P
15. 285750 A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y. Goto K, Masaki T Nature 1998 332 441-415 A complete study reporting the cloning of ET and its potent vasoconstricting activity. The paper also predicts that mature ET is generated through an unusual proteolytic processing, and that ET is possibly linked to the existence of a novel cardivascular control system. Includes details on the isolation, structural characterization and biological activity of ET.
16. 285753 The human endothelin family: The structurally and pharmacologically distinct isopeptides predicted by three separate genes. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T Proc Natl Acad Sci USA 1989 86 2863-2867
17. 285756 Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao WH, Kamada N et al Nature 1994 368 703-710
18. 296442 New Drugs in the R&D pipeline. Pharma Jpn 1998 1611 1
19. A-receptor antagonist, S-0139, on cerebral vasospasm and behavioral changes in dogs intracisternally administered endothelin-1. Sato S, Yonetani Y, Fujimoto M, Kita T, Kubo K, Nakashima T Life Sci 1998 62 13 PL191-PL197
20. A receptor subtype. Mihara SI, Tozawa F, Itazaki K, Fujimoto M Trends Anal Chem 1998 17 342 (2-3) 319-324
21. 301158 The endothelin system: A novel therapeutic target in cardiovascular disease. Strachan FE, Webb DJ Emerging Drugs 1998 3 95-112 A recent review on the role of endothelin in the cardiovascular system, and the application of drugs targeting the endothelin system as potential treatment for cardiovascular diseases.
22. 348554 Shionogi's new drugs R&D pipeline. Pharma Jpn 1999 1673 21
23. 349228 Japanese pharmaceutical industry. Lehman Brothers Inc 1999 August 25
24. 353641 Annual Report 1999 - Shionogi & Co Ltd. Shionogi & Co Ltd Annual Report 1999 June 29
25. 353660 Drugs under development. Shionogi & Co Ltd Company World Wide Web Site 2000 January 28
26. 370602 Drugs under development. Shionogi & Co Ltd Company World Wide Web Site 2000 June 12
27. 377901 Endothelin receptor antagonists: A clinical study update. Wu Wong JR, Padley R Curr Opin Cardiovasc Pulm Renal Invest Drugs 2000 2 4 339-344
28. 398750 Drugs under development. Shionogi & Co Ltd Company World Wide Web Site 2001 February 13
29. 410912 Drugs under development. Company World Wide Web Site 2001 May 29
30. 412732 2000 Annual Report: Shionogi & Co Ltd. Shionogi & Co Ltd Annual Report 2000 March 31
31. 416762 GSK and Shionogi to enter global multi-product development and commercialization alliance; GSK-Shionogi joint venture to be formed. GlaxoSmithKline Plc Press Release 2001 July 24
32. 416775 GlasoSmithKLine results announcement for the second quarter 2001. GlaxoSmithKline Plc Press Release 2001 July 24
33. 421267 Actelion Tracleer testicular toxicity in rats may show class effect, FDA says. FDC Reports Pink Sheet 2001 63 34 10-11
34. 425981 Drug development pipeline: S-1746. Shionogi & Co Ltd Company Communication 2001 October 17
35. 426569 GlaxoSmithKline results announcement for the third quarter 2001. GlaxoSmithKline Plc Press Release 2001 October 23
36. 426822 Final agreement reached on GSK-Shionogi joint venture project. Shionogi & Co Ltd Press Release 2001 October 24
37. 426830 Product development pipeline: October 2001. GlaxoSmithKline Plc Company Publication 2001 October 23
38. 429324 2001 Annual Report: Shionogi & Co Ltd. Shionogi & Co Ltd Annual Report 2001 March 31
39. 429990 Drugs under development. Shionogi & Co Ltd Company Communication 2001 November 12
40. 446957 Research & Development: Product Pipeline. GlaxoSmithKline Plc Company World Wide Web Site 2002 March 28
41. 449418 Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats. Matsuo Y, Mihara SI, Ninomiya M, Fujimoto M Stroke 2001 32 9 2143-2148
42. 449419 Endothelin-1 has a unique oxygen-saving effect by increasing contractile efficiency in the isolated rat heart. Takeuchi Y, Kihara Y, Inagaki K, Yoneda T, Sasayama S Circulation 2001 103 11 1557-1563
43. 449420 Highly enhanced disruption of blood-brain barrier permeability by repeated intracisternal administration of ET-1 in dogs. Narushima I, Kita T, Kubo K, Yonetani Y, Momochi C, Yosikawa I, Ohno N, Nakashima T Jpn J Pharmacol 2001 85 Suppl 1 287P
44. 449425 Endothelin receptor subtype antagonist activity of S-0139 in various isolated rabbit and canine arteries. Iwasaki T, Hayasaki Kajiwara Y, Shimamura T, Naya N, Nakajima M Eur J Pharmacol 2000 400 2-3 255-262
45. 449434 Therapy with the nonpeptide endothelin receptor antagonist 97-139 in a murine model of congestive heart failure: Reduction of cardiac mass and myofiber hypertrophy. Seta Y, Kanda T, Yokoyama T, Arai M, Sekiguchi K, Tanaka T, Kobayashi I, Kurabayashi M, Nagai R Jpn Heart J 2000 41 1 79-85
46. 449439 Contribution of endothelin-1 to disruption of blood-brain barrier permeability in dogs. Narushima I, Kita T, Kubo K, Yonetani Y, Momochi C, Yoshikawa I, Shimada K, Nakashima T Naunyn Schmiedebergs Arch Pharmacol 1999 360 6 639-645
47. 449442 Effects of endothelin receptor antagonists on anterior chamber inflammation induced by intravitreal injection of endothelin-1. Shoji N, Oshika T, Amano S, Masuda K Exp Eye Res 1999 69 4 437-444
48. 449446 A preventive effect of a selective endothelin-A receptor antagonist, S-0139, on the erythropoietin-induced reduction of the renal cortical blood flow. Ishikawa A, Suzuki K, Fujita K Urol Res 1999 27 5 312-314
49. 449449 Different roles of two types of endothelin receptors in partial ablation-induced chronic renal failure in rats. Shimizu T, Hata S, Kuroda T, Mihara S, Fujimoto M Eur J Pharmacol 1999 381 1 39-49
50. 449451 Potential contribution of endothelin to renal abnormalities in glycerol-induced acute renal failure in rats. Shimizu T, Kuroda T, Ikeda M, Hata S, Fujimoto M J Pharmacol Exp Ther 1998 286 2 977-983
51. 449456 Profiles of an intravenously available endothelin A-receptor antagonist, S-0139, for preventing cerebral vasospasm in a canine two-hemorrhage model. Kita T, Kubo K, Hiramatsu K, Sakaki T, Yonetani Y, Sato S, Fujimoto M, Nakashima T Life Sci 1998 63 4 305-315
52. 450707 Novel non-peptide endothelin antagonist isolated from bayberry, Myrica cerifera. Fujimoto M, Mihara S, Nakajima S, Ueda M, Nakamura M, Sakurai K FEBS Lett 1992 304 1 41-44
53. 450710 The endothelin ETA receptor-specific effect of 50-235, a nonpeptide endothelin antagonist. Mihara S, Fujimoto M Eur J Pharmacol 1993 246 1 33-38
54. 450711 Structure-activity relationships of an endothelin ETA receptor antagonist, 50-235, and its derivatives. Mihara S, Sakurai K, Nakamura M, Konoike T, Fujimoto M Eur J Pharmacol 1993 247 2 219-221
55. A receptors. Maguire JJ, Bacon CR, Fujimoto M, Davenport AP J Hypertens 1994 12 6 675-680
56. 450713 Endothelin receptor antagonist triterpenoid, myriceric acid A, isolated from Myrica cerifera, and structure activity relationships of its derivatives. Sakurawi K, Yasuda F, Tozyo T, Nakamura M, Sato T, Kikuchi J, Terui Y, Ikenishi Y, Iwata T, Takahashi K, Konoike T, Mihara S, Fujimoto M Chem Pharm Bull (Tokyo) 1996 44 2 343-351
57. 450714 Pharmacological characterization of a potent nonpeptide endothelin receptor antagonist, 97-139. Mihara S, Nakajima S, Matumura S, Kohnoike T, Fujimoto M J Pharmacol Exp Ther 1994 268 3 1122-1128
58. 450715 Signaling pathways crucial for craniofacial development revealed by endothelin-A receptor-deficient mice. Clouthier DE, Williams SC, Yanagisawa H, Wieduwilt M, Richardson JA, Yanagisawa M Dev Biol 2000 217 1 10-24
59. 450717 Clinical Trials Update. Genet Eng News 2002 22 6